Leyla Talan

Leyla Talan

Auto-generated profile, based on publicly available information

Leyla Talan

Department of Internal Medicine, Division of Intensive Care, Ankara University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
GGGoksel Guven
Goksel Guven
LTLeyla Talan
Leyla Talan
NANeriman Defne Altintas
Neriman Defne Altintas
KMKemal Osman Memikoglu
Kemal Osman Memikoglu
FYFugen Yoruk
Fugen Yoruk
AAAlpay Azap
Alpay Azap
Crimean-Congo hemorrhagic fever (CCHF) is a tick borne viral disease which can also be transmitted by direct contact with blood or tissue specimens of infected animals or humans. We present a fatal case of CCHF, who was diagnosed after death, and describe the post-exposure management plan for the health care workers (HCWs) involved in her care. In total of 52 HCWs were involved in the patient's care and they were stratified into risk groups. Overall, 20 HCWs were grouped in high and intermediate risk groups, including the HCW with needle stick injury. High and intermediate risk groups were offered post exposure prophlaxis (PEP) with ribavirin. Fourteen of 20 HCWs started PEP, however 10 ceased after negative CCHF-PCR results. Negative CCHF-PCR results were reported for all HCWs at the 5th day of exposure. Side effects with PEP developed in 5 of HCWs and were mainly gastrointestinal complaints which reversed after drug discontinuation. All HCWs were followed for 14 days both clinically and with laboratory tests. None of the HCWs developed CCHF. PEP with ribavirin can be considered as a safe option in protection.

22 September 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
KGKursat Gundogan
Kursat Gundogan
İAİsmail Hakkı Akbudak
İsmail Hakkı Akbudak
PHPervin Hancı
Pervin Hancı
BHBurcin Halaci
Burcin Halaci
STSahin Temel
Sahin Temel
ATArzu Topeli
Arzu Topeli
There are limited data on the long-term outcomes of COVID-19 from different parts of the world. To determine risk factors of 90-day mortality in critically ill patients in Turkish intensive care units (ICUs), with respiratory failure. Retrospective, observational cohort. Patients with laboratory-confirmed COVID-19 and who had been followed up in the ICUs with respiratory failure for more than 24 hours were included in the study. Their demographics, clinical characteristics, laboratory variables, treatment protocols, and survival data were recorded. A total of 421 patients were included. The median age was 67 (IQR: 57-76) years, and 251 patients (59.6%) were men. The 90-day mortality rate was 55.1%. The factors independently associated with 90-day mortality were invasive mechanical ventilation (IMV) (HR 4.09 [95% CI: [2.20-7.63], P < .001), lactate level >2 mmol/L (2.78 [1.93-4.01], P < .001), age ≥60 years (2.45 [1.48-4.06)], P < .001), cardiac arrhythmia during ICU stay (2.01 [1.27-3.20], P = .003), vasopressor treatment (1.94 [1.32-2.84], P = .001), positive fluid balance of ≥600 mL/day (1.68 [1.21-2.34], P = .002), PaO2/FiO2 ratio of ≤150 mmHg (1.66 [1.18-2.32], P = .003), and ECOG score ≥1 (1.42 [1.00-2.02], P = .050). Long-term mortality was high in critically ill patients with COVID-19 hospitalized in intensive care units in Turkey. Invasive mechanical ventilation, lactate level, age, cardiac arrhythmia, vasopressor therapy, positive fluid balance, severe hypoxemia and ECOG score were the independent risk factors for 90-day mortality.

31 December 2020 in Tuberk Toraks
Verified
Journal Article
Closed access
LTLeyla Talan
Leyla Talan
FSF. Gonca Şaşal Solmaz
F. Gonca Şaşal Solmaz
UEUğur Ercan
Uğur Ercan
İAİrem Akdemir
İrem Akdemir
BYBülent Mustafa Yenigün
Bülent Mustafa Yenigün
NAN. Defne Altıntaş
N. Defne Altıntaş
Barotrauma is a commonly reported complication in critically ill patients with ARDS caused by different etiologies, it's rate is reported to be around %10. Pneumothorax/pneumomediastinum in COVID-19 patients seem to be more common and have different clinical characteristics. Here we report 9 patients who had pneumothorax and/or pneumomediastinum during their stay in the ICU. Patients who were admitted to ICU between March 2020 and December 2020, were reviewed for presence of pneumothorax, pneumomediastinum and subcutaneous emphysema during their ICU stay. Demographic characteristics, mechanical ventilation settings, documented ventilation parameters, outcomes were studied. A total of 161 patients were admitted to ICU during the study period, 96 were invasively ventilated. Nine patients had developed pneumothorax, pneumomediastinum and/or subcutaneous emphysema during their admission. Five of them were men and median age was 66.6 years. All patients were intubated and mechanically ventilated. All patients were managed conservatively. One patient was discharged from ICU, the others were lost due to other complications related to COVID-19. Upon detection of pneumothorax and/or mediastinum all patients were managed conservatively by limiting their PEEP and maximum inspiratory pressures and were followed by daily chest X-rays (CXR) for detection of any progress. None of the patients showed increase in size of their pneumothorax and/or pneumomediastinum. Hemodynamically instability due to pneumothorax and/or pneumomediastinum was not observed in any of the patients. Tension pneumothorax was not observed in any of the patients. Most common reason for death was sepsis due to secondary bacterial infections. Acute deterioration with rapid oxygen desaturation or palpation of crepitation over thorax and neck in a COVID-19 patient should prompt a search for pneumothorax or pneumomediastinum. Conservative management may be an option as long as the patients are stable.

22 July 2022 in Balkan Medical Journal
Verified
Journal Article
Open access
LTLeyla Talan
Leyla Talan
İAİrem Akdemir
İrem Akdemir
NANeslihan Defne Altıntaş
Neslihan Defne Altıntaş
FYFügen Yörük
Fügen Yörük

3 September 2019 in European Journal of Rheumatology
Verified
Journal Article
Open access
GGGoksel Guven
Goksel Guven
AGAslihan Avanoglu Guler
Aslihan Avanoglu Guler
NONil OZYUNCU
Nil OZYUNCU
LTLeyla Talan
Leyla Talan
AHAylin Heper
Aylin Heper
NANeriman Defne Altıntaş
Neriman Defne Altıntaş
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may be triggered by hereditary factors, autoimmune and immunologic disorders, infectious diseases, malignancies and medications. Suspicion of the disease and early treatment is of paramount importance. Since the presentation of HLH with only skin involvement is rare, early diagnosis may be difficult. A pathologically confirmed HLH case that presented with maculopapular skin lesions after certolizumab treatment is being reported in this presentation. Cite this article as: Güven G, Güler A, Özyüncü N, Talan L, Heper A, Turgay TM, et al. Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis. Eur J Rheumatol 2018; 5(3): 203-5.

15 June 2021 in Tuberk Toraks
Verified
Journal Article
Closed access
AKAyca Koca
Ayca Koca
LTLeyla Talan
Leyla Talan
TŞTurgut Şahin
Turgut Şahin
GCGule Cinar
Gule Cinar
EEEbru Evren
Ebru Evren
ÖŞÖzden Şener
Özden Şener
COVID-19, caused by severe acute respiratory syndrome coronavirus-2, typically presents with respiratory symptoms and fever, but still a variety of clinical presentations have been reported. In this study, it was aimed to report a case of COVID-19 with an atypical presentation and an atypical course. As well, the recovery phase was complicated with CBS and consequently cyto-megalovirus infection. It should be kept in mind that patients with COVID-19 severe disease need to be followed for neurological and other complications which may arise during the course of critical illness.